Covid-19 roundup: EU begins reviewing Moderna vaccine; CureVac and EU agree to 405M-dose deal
A day after announcing their vaccine is highly effective at preventing Covid-19, Moderna said European regulators have begun a rolling review of the product for approval.
The news sets Moderna’s mRNA-1273 vaccine to be one of the first Covid-19 vaccines authorized on both sides of the Atlantic, with CEO Stéphane Bancel anticipating in an interview Sunday that the FDA will OK both their vaccine and the vaccine co-developed by Pfizer and BioNTech in early or mid-December. Neither company has yet submitted to the US agency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.